Adjuvant radiotherapy (adj RT) for extremity and trunk wall atypical lipomatous tumor/well-differentiated LPS (ALT/WD-LPS): A French Sarcoma Group (GSF-GETO) study.
Philippe Alexandre Cassier
Consultant or Advisory Role - Novartis (U)
Honoraria - GlaxoSmithKline; Novartis
Research Funding - Novartis; Roche
Guy Kantor
No relevant relationships to disclose
Sylvie Bonvalot
No relevant relationships to disclose
Emilie Lavergne
No relevant relationships to disclose
Eberhard Stoeckle
No relevant relationships to disclose
Cécile Le Pechoux
No relevant relationships to disclose
Pierre Meeus
No relevant relationships to disclose
Marie-Pierre Sunyach
No relevant relationships to disclose
Jean-Michel Coindre
No relevant relationships to disclose
Thomas Dubergé
No relevant relationships to disclose
Alain Labib
No relevant relationships to disclose
Jean-Leon Lagrange
No relevant relationships to disclose
Claude Linassier
No relevant relationships to disclose
Corinne Delcambre
No relevant relationships to disclose
Jacques-Olivier Bay
No relevant relationships to disclose
Serge Leyvraz
No relevant relationships to disclose
Nicolas Penel
Research Funding - Bayer; Janssen-Cilag; Novartis; PharmaMar; Roche
Sylvie Chabaud
No relevant relationships to disclose
Aude Duret
No relevant relationships to disclose
Jean-Yves Blay
Consultant or Advisory Role - GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Pfizer; PharmaMar; Roche
Honoraria - GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Pfizer; PharmaMar; Roche
Research Funding - GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Pfizer; PharmaMar; Roche
Expert Testimony - Merck Sharp & Dohme (U)